Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and ...

Rigel Pharmaceuticals (RIGL) announced the FDA has granted Orphan Drug designation to R289 for the treatment of myelodysplastic ...

Rigel Pharmaceuticals on Thursday said the U.S. Food and Drug Administration granted orphan-drug designation to its proposed R289 treatment for myelodysplastic syndromes, a group of rare blood cancers ...

Rigel Pharmaceuticals has shown significant growth, particularly from the acquisition of pralsetinib. Read why RIGL stock is ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and ...

U.S. stock markets witnessed an impressive rally in 2024 after an astonishing bull run in 2023. Following the 24.2% ascent in ...

Genomics companies analyze and interpret genetic information to uncover insights about genetic variations and disease ...

Rigel Pharmaceuticals has a 12 month low of $7.48 and a 12 month high of $29.82. The firm has a market capitalization of $305.09 million, a PE ratio of 123.72 and a beta of 1.22. About Rigel ...

Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL – Get Free Report) have earned an average rating of “Hold” from the five brokerages that are covering the stock, Marketbeat reports.

SOUTH SAN FRANCISCO, Calif., Jan. 3, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals ...

Rigel Pharmaceuticals (RIGL) announced that the U.S. Food and Drug Administration has granted Orphan Drug designation to R289 for the treatment ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has ...